Tirzepatide
A First-In-Human Study of ARO-INHBE in Adults With Obesity With and Without Type 2 Diabetes Mellitus
Eli Lilly · Phase 1/2 · Active, not recruiting · Enrollment 190
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Part 1: ARO-INHBE | n/r | n/r | n/r | n/r |
| Part 1: Placebo | n/r | n/r | n/r | n/r |
| Part 2: ARO-INHBE + Tirzepatide | n/r | n/r | n/r | n/r |
| Part 2: Placebo + Tirzepatide | n/r | n/r | n/r | n/r |
| Part 3: ARO-INHBE | n/r | n/r | n/r | n/r |
| Part 3: Placebo | n/r | n/r | n/r | n/r |
| Part 3: ARO-INHBE + Tirzepatide | n/r | n/r | n/r | n/r |
| Part 3: Placebo + Tirzepatide | n/r | n/r | n/r | n/r |
Not shown
- Part 1: ARO-INHBE: endpoint not reported
- Part 1: Placebo: endpoint not reported
- Part 2: ARO-INHBE + Tirzepatide: endpoint not reported
- Part 2: Placebo + Tirzepatide: endpoint not reported
- Part 3: ARO-INHBE: endpoint not reported
- Part 3: Placebo: endpoint not reported
- Part 3: ARO-INHBE + Tirzepatide: endpoint not reported
- Part 3: Placebo + Tirzepatide: endpoint not reported